SGX:Q0F

Stock Analysis Report

IHH Healthcare Berhad

Executive Summary

IHH Healthcare Berhad, an investment holding company, provides healthcare services worldwide.

Snowflake

Fundamentals

Reasonable growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has IHH Healthcare Berhad's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.1%

Q0F

0.8%

SG Healthcare

0.9%

SG Market


1 Year Return

2.2%

Q0F

-14.6%

SG Healthcare

0.4%

SG Market

Return vs Industry: Q0F exceeded the SG Healthcare industry which returned -14.6% over the past year.

Return vs Market: Q0F exceeded the SG Market which returned 0.4% over the past year.


Share holder returns

Q0FIndustryMarket
7 Day-1.1%0.8%0.9%
30 Day-1.1%1.9%-2.1%
90 Day-2.7%-5.9%-7.0%
1 Year2.8%2.2%-13.2%-14.6%4.4%0.4%
3 Year-11.5%-12.9%-20.3%-25.2%15.5%3.1%
5 Year2.3%-0.3%-13.7%-22.8%11.6%-6.9%

Price Volatility Vs. Market

How volatile is IHH Healthcare Berhad's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is IHH Healthcare Berhad undervalued based on future cash flows and its price relative to the stock market?

26%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: Q0F (SGD1.83) is trading below our estimate of fair value (SGD2.46)

Significantly Undervalued: Q0F is trading below fair value, but not by a significant amount.


Price Based on Earnings

PE vs Industry: Q0F is poor value based on its PE Ratio (81.6x) compared to the Healthcare industry average (27.2x).

PE vs Market: Q0F is poor value based on its PE Ratio (81.6x) compared to the SG market (13.3x).


Price Based on Expected Growth

Low PEG Ratio: Q0F is poor value based on its PEG Ratio (3.3x)


Price Based on Value of Assets

PB vs Industry: Q0F is good value based on its PB Ratio (2x) compared to the SG Healthcare industry average (2.3x).


Next Steps

Future Growth

How is IHH Healthcare Berhad expected to perform in the next 1 to 3 years based on estimates from 19 analysts?

24.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: Q0F's forecast earnings growth (24.9% per year) is above the savings rate (2.3%).

Earnings vs Market: Q0F's earnings (24.9% per year) are forecast to grow faster than the SG market (5.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Q0F's revenue (9.8% per year) is forecast to grow faster than the SG market (5.4% per year).

High Growth Revenue: Q0F's revenue (9.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Q0F's Return on Equity is forecast to be low in 3 years time (5.3%).


Next Steps

Past Performance

How has IHH Healthcare Berhad performed over the past 5 years?

-9.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Q0F's earnings have declined by -9.9% per year over the past 5 years.

Accelerating Growth: Q0F's earnings growth over the past year (81.8%) exceeds its 5-year average (-9.9% per year).

Earnings vs Industry: Q0F earnings growth over the past year (81.8%) exceeded the Healthcare industry -13.3%.


Return on Equity

High ROE: Q0F's Return on Equity (1.9%) is considered low.


Return on Assets

ROA vs Industry: Q0F's Return on Assets is below or equal to the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: Q0F has improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is IHH Healthcare Berhad's financial position?


Financial Position Analysis

Short Term Liabilities: Q0F's short term assets (SGD7.9B) exceeds its short term liabilities (SGD6.6B)

Long Term Liabilities: Q0F's short term assets (SGD7.9B) do not cover its long term liabilities (SGD11.1B)


Debt to Equity History and Analysis

Debt Level: Q0F's debt to equity ratio (32.8%) is considered satisfactory

Reducing Debt: Q0F's debt to equity ratio has increased from 20.6% to 32.8% over the past 5 years.

Debt Coverage: Q0F's debt is well covered by operating cash flow (21.4%).

Interest Coverage: Q0F's interest payments on its debt are well covered by EBIT (6.1x coverage).


Balance Sheet

Inventory Level: Q0F has a high level of physical assets or inventory.

Debt Coverage by Assets: Q0F's debt is not covered by short term assets (assets are 0.8x debt).


Next Steps

Dividend

What is IHH Healthcare Berhad's current dividend yield, its reliability and sustainability?

0.67%

Expected Dividend Yield


Dividend Yield vs Market

company0.5%marketbottom25%2.5%markettop25%5.6%industryaverage3.5%forecastin3Years0.7%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Q0F's dividend (0.53%) isn’t notable compared to the bottom 25% of dividend payers in the SG market (2.5%).

High Dividend: Q0F's dividend (0.53%) is low compared to the top 25% of dividend payers in the SG market (5.57%).

Stable Dividend: Q0F is not paying a notable dividend for the SG market, therefore no need to check if payments are stable.

Growing Dividend: Q0F is not paying a notable dividend for the SG market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: Q0F is not paying a notable dividend for .


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of Q0F's dividend in 3 years as they are not forecast to pay a notable one for the SG market.


Next Steps

Management

What is the CEO of IHH Healthcare Berhad's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

See Leng Tan (54yo)

5.8yrs

Tenure

RM36,175,000

Compensation

Dr. See Leng Tan serves as the Group Chief Executive Officer and Managing Director at Parkway Pantai Limited. Dr. Tan serves as an Advisor at Clearbridge Accelerator. He has been the Chief Executive Office ...


CEO Compensation Analysis

Compensation vs. Market: See Leng's total compensation ($USD8.64M) is above average for companies of similar size in the SG market ($USD3.36M).

Compensation vs Earnings: See Leng's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.6yrs

Average Tenure

54yo

Average Age

Experienced Management: Q0F's management team is considered experienced (2.6 years average tenure).


Board Age and Tenure

2.5yrs

Average Tenure

56yo

Average Age

Experienced Board: Q0F's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Soon Teck Low (54yo)

    Group Chief Financial Officer

    • Tenure: 3.8yrs
  • See Leng Tan (54yo)

    CEO, MD & Non-Independent Executive Director

    • Tenure: 5.8yrs
    • Compensation: RM36.18m
  • Mehmet Aydinlar (62yo)

    • Tenure: 0yrs
    • Compensation: RM7.72m
  • Boon Kheng Chan (51yo)

    Group Head of Strategic Planning & Business Development (M&A) and CEO of South East Asia Ops. Div.

    • Tenure: 1.8yrs
  • Suet Wun Lim (59yo)

    Group Chief Operating Officer

    • Tenure: 1.6yrs
  • Ching Voon Seow

    Company Secretary

    • Tenure: 0yrs
  • Nili Shayrina Saat (44yo)

    Head of Risk Management

    • Tenure: 0.9yrs
  • Kelvin Loh (45yo)

    Executive Director

    • Tenure: 0.3yrs
  • Abdul Baba (63yo)

    President of IMU Health Sdn Bhd and C.E.O. & Vice-Chancellor of IMU Education Sdn Bhd

    • Tenure: 3.8yrs
  • Sharon Lin (50yo)

    Group Chief Human Resources Officer

    • Tenure: 2.6yrs

Board Members

  • Shirish Apte (66yo)

    Independent Non-Executive Director

    • Tenure: 5.1yrs
    • Compensation: RM722.00k
  • Mohammed Bin Hashim (62yo)

    Independent Non Executive Chairman

    • Tenure: 1.8yrs
    • Compensation: RM985.00k
  • See Leng Tan (54yo)

    CEO, MD & Non-Independent Executive Director

    • Tenure: 5.8yrs
    • Compensation: RM36.18m
  • Mehmet Aydinlar (62yo)

    • Tenure: 0yrs
    • Compensation: RM7.72m
  • Jill Watts (60yo)

    Independent Non Executive Director

    • Tenure: 1.5yrs
    • Compensation: RM337.00k
  • Koji Nagatomi (58yo)

    Non Independent & Non Executive Director

    • Tenure: 2.5yrs
    • Compensation: RM295.00k
  • Rossana Binti Ahmad Rashid (53yo)

    Independent Non-Executive Director

    • Tenure: 7.5yrs
    • Compensation: RM867.00k
  • Kelvin Loh (45yo)

    Executive Director

    • Tenure: 0.3yrs
  • Takeshi Saito (47yo)

    Non-Independent & Non-Executive Director

    • Tenure: 0.6yrs
    • Compensation: RM148.00k
  • Chinta Bhagat (50yo)

    Non-Independent Non-Executive Director

    • Tenure: 3.1yrs
    • Compensation: RM626.00k

Company Information

IHH Healthcare Berhad's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IHH Healthcare Berhad
  • Ticker: Q0F
  • Exchange: SGX
  • Founded: 2010
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: RM49.573b
  • Listing Market Cap: RM16.243b
  • Shares outstanding: 8.77b
  • Website: https://www.ihhhealthcare.com

Number of Employees


Location

  • IHH Healthcare Berhad
  • Pantai Hospital Kuala Lumpur
  • Level 11, Block A
  • Kuala Lumpur
  • Wilayah Persekutuan
  • 59100
  • Malaysia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IHHKLSE (Bursa Malaysia)YesOrdinary SharesMYMYRJul 2012
Q0FSGX (Singapore Exchange)YesOrdinary SharesSGSGDJul 2012
IHHH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2012

Biography

IHH Healthcare Berhad, an investment holding company, provides healthcare services worldwide. The company operates in seven segments: Singapore, Malaysia, India, North Asia, Acibadem Holdings, IMU Health,  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 13:11
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)